Alex Duncan PhD

Alex Duncan as Chief Technology Officer and Head of Research, Alex is responsible for closely aligning research and Manufacturing Technology to deliver manufacturable and innovative development candidates across our different drug modalities. In his prior role as Chief Technology Officer, Alex directed the modernization and optimization of our technical platforms and is responsible for all manufacturing and quality systems including those relating to Prophage. Alex is a seasoned antibody research scientist and business leader with over 20 years of experience leading antibody technology and biotherapeutic drug discovery programs in all major therapy areas. He joined Agenus in January 2015 from Actigen, a company focused on development of immunomodulatory antibody compounds, where he was Managing Director. Previously, Alex was CSO and Head of R&D at Affitech A/S (Denmark) and a member of the Astra Zeneca Discovery senior management team, where he served as Senior Vice President Biopharmaceuticals and led the Cambridge UK Discovery site, previously Cambridge Antibody Technology (CAT). Prior to its acquisition by Astra Zeneca, Alex was SVP Drug Discovery at CAT, where he built a recognized world-class antibody discovery capability. Technology developed by CAT was used to create adalimumab, the first fully human antibody blockbuster drug known commercially as Humira. Alex gained his PhD in Dr. Sir Greg Winter’s laboratory at the MRC Laboratory of Molecular Biology, University of Cambridge and held post-doctoral positions at the University of California San Diego.